Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
3,703 stopped studies mapped to Carcinoma and descendants · 91% state a reason
Over the 3,703 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04748419 | Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting… | Phase 1 / Phase 2 | terminated | Feb 10, 2021 | University of Nebraska | Poor accrual | Enrollment / accrual |
| NCT05110781 | Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck… | Phase 2 | terminated | Nov 8, 2021 | University of California, Davis | Slow accrual | Enrollment / accrual |
| NCT04189614 | An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With… | Phase 1 | terminated | Dec 6, 2019 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT04955743 | Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal… | Phase 2 | terminated | Jul 9, 2021 | Yale University | Lack of activity in the drugs | Other (stated, no rule matched) |
| NCT05183828 | Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer | Phase 4 | terminated | Jan 11, 2022 | University of Washington | Study ended earlier than anticipated due to end of funding. | Funding |
| NCT05316467 | Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma | Phase 2 / Phase 3 | terminated | Apr 7, 2022 | Xiaojun Chen | no enough enrolled patients | Enrollment / accrual |
| NCT05419479 | Switch Maintenance in Pancreatic | Phase 1 / Phase 2 | suspended | Jun 15, 2022 | James Cleary, MD, PhD | Efficacy concerns. | Efficacy / futility |
| NCT06351332 | ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC | Phase 1 | terminated | Apr 8, 2024 | Filipa Lynce, MD | Zentalis terminated contract due to concern for toxicity safety from previously reported serious… | Safety / toxicity |
| NCT05062980 | Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously…(Acclaim-2) | Phase 1 | terminated | Sep 30, 2021 | Genprex, Inc. | Enrollment was slow, due to competition with the many other clinical trials for the same patient… | Enrollment / accrual |
| NCT05523440 | Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer… | Phase 2 | terminated | Aug 31, 2022 | University of Oklahoma | Funding issue | Funding |
| NCT03331601 | Evaluation of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Cancer Patients | Phase 2 | terminated | Nov 6, 2017 | Universitair Ziekenhuis Brussel | Delay in recruitment | Enrollment / accrual |
| NCT05275075 | Identify microRNAs in Cachexia in Pancreatic Carcinoma(SCC-miRPanCa) | — | terminated | Mar 11, 2022 | University of Oklahoma | Translational scientist left university | Other (stated, no rule matched) |
| NCT06171789 | PRO1107 in Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Dec 15, 2023 | Genmab | Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk… | Other (stated, no rule matched) |
| NCT06558799 | LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With…(LUNAR-4) | Phase 2 | terminated | Aug 19, 2024 | NovoCure GmbH | EF-50/LUNAR-4 was terminated because available real-world data are expected to enable Novocure to… | Safety / toxicity |
| NCT03199885 | Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive… | Phase 3 | terminated | Jun 27, 2017 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT03402880 | ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small… | Phase 2 | withdrawn | Jan 18, 2018 | City of Hope Medical Center | No patients enrolled | Enrollment / accrual |
| NCT06405061 | Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and… | Phase 2 | suspended | May 8, 2024 | Tianjin Medical University Cancer Institute and Hospital | Mid-term data analysis for the project has been completed; enrollment is now suspended. | Enrollment / accrual |
| NCT06878248 | A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast… | Phase 1 | terminated | Mar 14, 2025 | Calibr, a division of Scripps Research | Business Decision | Sponsor / business decision |
| NCT03237377 | Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer | Phase 2 | terminated | Aug 2, 2017 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | low accrual | Enrollment / accrual |
| NCT03520686 | Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer | Phase 3 | terminated | May 11, 2018 | ImmunityBio, Inc. | There are no longer active subjects on QUILT-2.023. Data will be entered into clinicaltrials.gov… | Other (stated, no rule matched) |
| NCT06391099 | Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With… | N/A | suspended | Apr 30, 2024 | Ohio State University Comprehensive Cancer Center | pending amendment | Other (stated, no rule matched) |
| NCT02106572 | Therapeutic Instillation of Mistletoe(TIM) | Phase 3 | terminated | Apr 8, 2014 | Abnoba Gmbh | The study was terminated because the required number of patients cannot be reached in the… | Safety / toxicity |
| NCT03324282 | First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder…(GCISAVE) | Phase 2 | terminated | Oct 27, 2017 | University Hospital, Bordeaux | ANSM's refusal to validate ATU requests for avelumab in bladder cancer, Decrease in recruitment,… | Enrollment / accrual |
| NCT03646461 | Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic… | Phase 2 | terminated | Aug 24, 2018 | University of California, San Diego | Lack of scientific process of cancer-related clinical intervention | Other (stated, no rule matched) |
| NCT04169074 | Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM… | Phase 2 | terminated | Nov 19, 2019 | University of Arizona | Standard of care therapy for Stage III-IVA HNSCC updated in June to include neoadjuvant + adjuvant… | Other (stated, no rule matched) |
| NCT04975217 | Fecal Microbial Transplants for the Treatment of Pancreatic Cancer | Early Phase 1 | suspended | Jul 23, 2021 | M.D. Anderson Cancer Center | PI request | Other (stated, no rule matched) |
| NCT06685718 | A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor… | Phase 1 | terminated | Nov 12, 2024 | BeOne Medicines | Evaluation on business strategy, not involving safety issue. | Safety / toxicity |
| NCT06704724 | A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other… | Phase 1 | terminated | Nov 26, 2024 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT04588246 | Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to… | Phase 3 | terminated | Oct 19, 2020 | NRG Oncology | Inadequate accrual rate | Enrollment / accrual |
| NCT07551544 | ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed… | Phase 3 | withdrawn | Apr 27, 2026 | ImmunityBio, Inc. | Sponsor decision | Sponsor / business decision |
| NCT05368428 | Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy… | N/A | terminated | May 10, 2022 | Emory University | PI Decision | Other (stated, no rule matched) |
| NCT01552434 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in… | Phase 1 | terminated | Mar 13, 2012 | M.D. Anderson Cancer Center | \< 75 % participation | Other (stated, no rule matched) |
| NCT03437941 | Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients… | Phase 1 / Phase 2 | terminated | Feb 19, 2018 | Corcept Therapeutics | The level of benefit observed did not justify enrolling patients in the Dose Expansion phase of the… | Enrollment / accrual |
| NCT03645928 | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | Phase 2 | terminated | Aug 24, 2018 | Iovance Biotherapeutics, Inc. | After reviewing the available safety and efficacy data to date, Iovance concluded that the study… | Safety / toxicity |
| NCT04716725 | 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer | Phase 2 | terminated | Jan 20, 2021 | Thomas Hope | Low accrual | Enrollment / accrual |
| NCT05051345 | Increasing Access to Smoking Cessation and Smoke Free Home Services for Low-Income… | N/A | terminated | Sep 21, 2021 | M.D. Anderson Cancer Center | \< 75% participation | Other (stated, no rule matched) |
| NCT03825289 | Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer(THREAD) | Phase 1 | terminated | Jan 31, 2019 | University of Utah | Lack of Funding | Funding |
| NCT04030559 | Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer… | Phase 2 | terminated | Jul 24, 2019 | University of California, Davis | PI choice; poor accrual | Enrollment / accrual |
| NCT05223036 | Testing Obeticholic Acid for Familial Adenomatous Polyposis | Phase 2 | terminated | Feb 3, 2022 | National Cancer Institute (NCI) | Protocol has been completed prematurely due to poor accrual and study feasibility. | Enrollment / accrual |
| NCT04955808 | Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate,… | — | suspended | Jul 9, 2021 | National Cancer Institute (NCI) | Due to slow accrual on this trial, we will allow sites time to work on close-out procedures and… | Enrollment / accrual |
| NCT06844669 | HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving… | Phase 2 | terminated | Feb 25, 2025 | Washington University School of Medicine | Futility | Efficacy / futility |
| NCT03337698 | A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With…(Morpheus Lung) | Phase 1 / Phase 2 | terminated | Nov 9, 2017 | Hoffmann-La Roche | Study was closed early as the sponsor decided not to continue development of certain treatment… | Sponsor / business decision |
| NCT04025515 | Molecular Profiling Project | — | suspended | Jul 19, 2019 | National Cancer Centre, Singapore | Discussion under way on how to continue/restart the study in view of slow recruitment rate. | Enrollment / accrual |
| NCT04746924 | A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With… | Phase 3 | terminated | Feb 10, 2021 | BeiGene | This decision was conducted by the sponsor based on lack of efficacy and not driven by safety… | Safety / toxicity |
| NCT02928627 | Clinical Significance of Hepatic and Circulating microRNAs miR-221 and miR-222 in… | — | terminated | Oct 10, 2016 | University of Aberdeen | The project did not progress as there were no findings available for the lab analysis of microRNA… | Other (stated, no rule matched) |
| NCT04878952 | Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve… | N/A | terminated | May 10, 2021 | NRG Oncology | will not be able to meet study accrual objectives. | Enrollment / accrual |
| NCT05200442 | A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer | Phase 1 / Phase 2 | suspended | Jan 20, 2022 | University of Chicago | enrollment goal met pending determination of evaluable subjects | Enrollment / accrual |
| NCT06295809 | A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous…(INTerpath-007) | Phase 2 / Phase 3 | terminated | Mar 6, 2024 | Merck Sharp & Dohme LLC | Business reasons | Sponsor / business decision |
| NCT06708936 | KSD-201 Treatment for Advanced Clear Cell Renal Cell Carcinoma: an Early Exploratory… | Early Phase 1 | withdrawn | Nov 29, 2024 | Kousai Bio Co., Ltd. | Due to a strategic adjustment, the company has decided to terminate the project. | Sponsor / business decision |
| NCT06870487 | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced… | Phase 1 | terminated | Mar 11, 2025 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jun 5, 2026source: clinicaltrials